Terms: = Breast cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Clinical Outcome
25 results:
1. Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
Parks RM; Albanghali MA; Syed BM; Green AR; Ellis IO; Cheung KL
Breast Cancer Res Treat; 2021 Feb; 185(3):647-655. PubMed ID: 33226492
[TBL] [Abstract] [Full Text] [Related]
2. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Li L; Lin L; Veeraraghavan J; Hu Y; Wang X; Lee S; Tan Y; Schiff R; Wang XS
Breast Cancer Res; 2020 Aug; 22(1):84. PubMed ID: 32771039
[TBL] [Abstract] [Full Text] [Related]
3. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
[TBL] [Abstract] [Full Text] [Related]
4. Heregulin/erbb3 Signaling Enhances CXCR4-Driven Rac1 Activation and breast cancer Cell Motility via Hypoxia-Inducible Factor 1α.
Lopez-Haber C; Barrio-Real L; Casado-Medrano V; Kazanietz MG
Mol Cell Biol; 2016 Aug; 36(15):2011-26. PubMed ID: 27185877
[TBL] [Abstract] [Full Text] [Related]
5. A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing breast cancer.
Menyhárt O; Santarpia L; Győrffy B
Curr Cancer Drug Targets; 2015; 15(8):665-83. PubMed ID: 26452383
[TBL] [Abstract] [Full Text] [Related]
6. Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: A retrospective study.
Jiao S; Liu W; Wu M; Peng C; Tang H; Xie X
Cancer Biomark; 2015; 15(2):115-23. PubMed ID: 25519010
[TBL] [Abstract] [Full Text] [Related]
7. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
Baselga J; Cortés J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM
J Clin Oncol; 2014 Nov; 32(33):3753-61. PubMed ID: 25332247
[TBL] [Abstract] [Full Text] [Related]
8. Co-overexpression of HER2/her3 is a predictor of impaired survival in breast cancer patients.
Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
[TBL] [Abstract] [Full Text] [Related]
9. An heregulin-EGFR-her3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract] [Full Text] [Related]
10. Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts.
Syed BM; Green AR; Paish EC; Soria D; Garibaldi J; Morgan L; Morgan DA; Ellis IO; Cheung KL
Br J Cancer; 2013 Mar; 108(5):1042-51. PubMed ID: 23462719
[TBL] [Abstract] [Full Text] [Related]
11. Correlation of HER2, p95HER2 and her3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Han SW; Cha Y; Paquet A; Huang W; Weidler J; Lie Y; Sherwood T; Bates M; Haddad M; Park IH; Oh DY; Lee KS; Im SA; Bang YJ; Ro J; Kim TY
PLoS One; 2012; 7(7):e39943. PubMed ID: 22848366
[TBL] [Abstract] [Full Text] [Related]
12. HER-3 status by immunohistochemistry in HER-2-positive metastatic breast cancer patients treated with trastuzumab: correlation with clinical outcome.
Gori S; Foglietta J; Mameli MG; Stocchi L; Fenocchio D; Anastasi P; Iacono D; Del Sordo R; Basurto C; De Angelis V; Sidoni A
Tumori; 2012; 98(1):39-44. PubMed ID: 22495700
[TBL] [Abstract] [Full Text] [Related]
13. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract] [Full Text] [Related]
14. Expression of epidermal growth factor receptor or erbb3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract] [Full Text] [Related]
15. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.
Jin Q; Esteva FJ
J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):485-98. PubMed ID: 19034632
[TBL] [Abstract] [Full Text] [Related]
16. Cytogenetic analysis of HER1/EGFR, HER2, her3 and HER4 in 278 breast cancer patients.
Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
[TBL] [Abstract] [Full Text] [Related]
17. Correlated expression of erbb-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A
Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331
[TBL] [Abstract] [Full Text] [Related]
18. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Giuliani R; Durbecq V; Di Leo A; Paesmans M; Larsimont D; Leroy JY; Borms M; Vindevoghel A; Jerusalem G; D'Hondt V; Dirix L; Canon JL; Richard V; Cocquyt V; Majois F; Reginster M; Demol J; Kains JP; Delree P; Keppens C; Sotiriou C; Piccart MJ; Cardoso F
Eur J Cancer; 2007 Mar; 43(4):725-35. PubMed ID: 17251007
[TBL] [Abstract] [Full Text] [Related]
19. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
[TBL] [Abstract] [Full Text] [Related]
20. outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.
Tovey SM; Witton CJ; Bartlett JM; Stanton PD; Reeves JR; Cooke TG
Breast Cancer Res; 2004; 6(3):R246-51. PubMed ID: 15084248
[TBL] [Abstract] [Full Text] [Related]
[Next]
